Efficacy and safety of Banxia Xiexin Decoction in the treatment of gastric ulcer:a systematic review and meta-analysis of twenty-seven randomized controlled trials

Background:Banxia XieXin Decoction(BXD)is a traditional Chinese medicine decoction commonly used in the Chinese clinical treatment of gastric ulcer(GU).Although some people believe that it may have some advantages in this regard,There is no reliable evidence-based study demonstrating its effectiveness.This study aims to systematically evaluate the healing effect and security of BXD in the treatment of GU.Methods:PubMed,Cochrane Library,EMBASE,ScienceNet,China National Knowledge Infrastructure(CNKI),Wanfang database,Weipu database,and China biomedical literature service(CBM)database were systematically searched to obtain all randomized controlled trials(RCTs)evaluating the treatment GU of BXD published as of April 2022.Two researchers independently screened and extracted all research data,finally evaluated the bias risk of inclusion in the study using revman 5.4.Results:This meta-analysis included 27 randomized controlled trials and 1411 patients.The clinical effective rate,recurrence rate,HP eradication rate,adverse reaction rate,and visual analog score(VAS)of BXD combined treatment and standard treatment alone were compared.The results of the meta-analysis showed that BXD combined treatment improve the symptoms related to the gastric ulcers and reduce drug-related adverse reactions.Due to the low quality of the research included in this analysis,in-depth high-quality research is crucial for verifying these results.

BanXiaXieXin decoction treating gastritis mice with drug-resistant Helicobacter pylori and its mechanism

BACKGROUND Helicobacter pylori(H.pylori)is the main pathogen that causes a variety of upper digestive diseases.The drug resistance rate of H.pylori is increasingly higher,and the eradication rate is increasingly lower.The antimicrobial resistance of H.pylori is an urgent global problem.It has been confirmed that Banxia Xiexin decoction(BXXXT)demonstrates the effects of treating gastrointestinal diseases,inhibiting H.pylori and protecting gastric mucosa.The purpose of the present study is to further explore the therapeutic effects of BXXXT on drug-resistant H.pylori.AIM To confirm that BXXXT demonstrates therapeutical effects in vivo and in vitro on gastritis mice with drug-resistant H.pylori and explain its mechanism to provide an experimental basis for promoting the application of BXXXT.METHODS The aqueous extract of BXXXT was gained by water decocting method.The inhibitory effect of the aqueous extract on H.pylori was detected by dilution in vitro;drug-resistant H.pylori cells were used to build an acute gastritis model in vivo.Thereafter,the model mice were treated with the aqueous extract of BXXXT.The amount of H.pylori colonization,the repair of gastric mucosal damage,changes of inflammatory factors,apoptosis,etc.,were assessed.In terms of mechanism exploration,the main medicinal compositions of BXXXT aqueous extract and the synergistic bacteriostatic effects they had demonstrated were analyzed using mass spectrometry;the immune function of peripheral blood cells such as CD3+T and CD4+T of mice with gastritis before and after treatment with BXXXT aqueous extract was detected using a flow cytometry;the H.pylori transcriptome and proteome after treatment with BXXXT aqueous extract were detected.Differently expressed genes were screened and verification was performed thereon with knockout expression.RESULTS The minimum inhibitory concentration of BXXXT aqueous extract against H.pylori was 256-512μg/mL.A dose of 28 mg/kg BXXXT aqueous extract treatment produced better therapeutical effects than the standard triple therapy did;the BXXXT aqueous extract have at least 11 ingredients inhibiting H.pylori,including berberine,quercetin,baicalin,luteolin,gallic acid,rosmarinic acid,aloe emodin,etc.,of which berberine,aloe emodin,luteolin and gallic acid have a synergistic effect;BXXXT aqueous extract was found to stimulate the expressions of CD3+T and CD4+T and increase the number of CD4+T/CD8+T in gastritis mice;the detection of transcriptome and proteome,quantitative polymerase chain reaction,Western blotting and knockout verification revealed that the main targets of BXXXT aqueous extract are CFAs related to urea enzymes,and CagA,VacA,etc.CONCLUSION BXXXT aqueous extract could demonstrate good therapeutic effects on drug-resistance H.pylori in vitro and in vivo and its mechanism comes down to the synergistic or additional antibacterial effects of berberine,emodin and luteolin,the main components of the extract;the extract could activate the immune function and enhance bactericidal effects;BXXXT aqueous extract,with main targets of BXXXT aqueous extract related to urease,virulence factors,etc.,could reduce the urease and virulence of H.pylori,weaken its colonization,and reduce its inflammatory damage to the gastric mucosa.

Research progress and clinical experience of Banxia Xiexin Decoction in the treatment of insomnia

Insomnia is a common clinical disease.At present,with the increase of work and life pressure,the incidence of insomnia is increasing year by year,which seriously affects people's physical and mental health and quality of life.Although stable drugs are effective in the treatment of insomnia,they have long-term side effects.Traditional Chinese medicine has unique advantages in the treatment of insomnia.Among them,Banxia Xiexin Decoction is based on the theory of"stomach disorder,sleep restlessness".Curative effect.By searching relevant literature,this article discusses the research progress of Banxia Xiexin Decoction in the treatment of insomnia from the theory,prescription and clinical research of Banxia Xiexin Decoction,and describes the clinical experience of using Banxia Xiexin Decoction.In order to provide some reference for the clinic.

Network pharmacology analysis of the mechanisms of Banxia Xiexin Decoction against Ulcerative Colitis

Banxia Xiexin Decoction(BXXXD),a traditional herbal formula,has been used to treat ulcerative colitis(UC)clinically.In this study,chemical compounds and putative targets of BXXXD and UC related therapeutic targets were screened from multiple databases.The protein-protein interaction(PPI)was conducted using String database,and 31 candidate targets were screened from CytoNCA database.The Database for Annotation,Visualization and Integrated Discovery(DAVID)and Metascape database were used for Kyoto Encyclopedia of Genes and Genomes(KEGG)channel and Gene Ontology(GO)enrichment analysis respectively,and the enrichment analysis results were visualized by OmicShare platform.Meanwhile,the interaction network among Chinese herbs,active compounds,candidate targets and pathways was built by Cytoscape 3.7.2 software,and the potential compounds of BXXXD in the treatment of UC were screened.Finally,molecular docking technology was used to verify the putative key compounds.Combined with literature research,5 key compounds for the treatment of UC were identified,which are mainly involved in TNF signaling pathway,cancer signaling pathway,inflammatory bowel disease(IBD),Toll-like receptor signaling pathway,and NF-κB signaling pathway.This study provides a scientific basis for BXXXD as an effective alternative therapeutic agent for UC from a new perspective,and also provides a feasible method for basic chemical research and pharmacological research of BXXXD.

Discussion on the Theoretical Basis of Banxia Xiexin Decoction in the Treatment of Insulin Resistance Obesity

Through reading Chinese ancient book Huangdi Nejing,and summarizing and analyzing related literature,the basic pathogenesis of obesity have been found to be the stomach preponderance and spleen weakness,and the imbalance of ascending and descending.Banxia Xiexin Decoction not only has the functions of relieving heat to inhibit stomach intake,supplementing deficiency to assist spleen transport,regulate the ascending and descending,but also has the effects of improving insulin resistance and regulating glucolipid metabolism.Therefore,it is suggested that Banxia Xiexin Decoction can be used in the treatment of insulin resistant obesity,which provides ideas and methods for its treatment.

Systematic Review and Meta-analysis of Efficacy of Banxia Xiexin Decoction for Treatment of Bile Reflux Gastritis

[Objectives]The purpose was to study the clinical efficacy and safety of Banxia Xiexin decoction in treating bile reflux gastritis(BRG).[Methods]Randomized controlled trial was adopted to conduct scientific and standardized assessment on the risk of bias in the included articles.With overall effect and epigastric pain relief as indices,meta-analysis was performed,and sensitivity and safety analysis was conducted on the included literature.[Results]A total of 13 articles were included,involving a total of 1478 patients.The results of meta-analysis show that the efficacy of Banxia Xiexin decoction alone and Banxia Xiexin decoction-Western medicine combination is better than that of Western medicine alone.[Conclusions]Banxia Xiexin decoction is safe and effective in treating bile reflux gastritis.However,as the 13 articles included are all low in quality and there is a certain degree of publication bias,the objectivity of the results is affected to some extent.

Banxia Xiexin Decoction for patients with peptic ulcer or chronic gastritis infected with Helicobacter pylori

Objective:To compare the effectiveness and safety of Banxia Xiexin Decoction (BXD) as alternative therapy versus standard triple therapy or quadruple therapy for patients with peptic ulcer or chronic gastritis infected with Helicobacter pylori (H.pylori).Methods:Databases including China National Knowledge Infrastructure,Chongqing VIP,Wanfang Database,PubMed,the Cochrane Library and clinicaltrials.gov were searched in December 2018 for relevant randomized controlled trials (RCTs).Two authors independently screened and selected studies,extracted data and checked data extraction.Methodological quality was evaluated using the Cochrane Risk of Bias tool.Meta-analysis was performed by using RevMan 5.3.5 software.Results:Fourteen RCTs were included in our analysis involving 1300 patients.Thirteen RCTs compared the effects of BXD alone versus standard therapy,11 involving triple therapy and 2 in quadruple therapy.The cure rate for both diseases were higher in the BXD alone group than in the standard therapy group (RR and 95% Cl:1.85 [1.07,3.17] and 1.48 [1.24,1.75],respectively).And also,the same result with effectiveness rate (RR and 95% CI:1.18 [1.08,1.29] and 1.14 [1.08,1.20],respectively).However,there was no significant difference in the clearance of H.pylori one month after treatment,neither compared with quadruple therapy nor triple therapy (RR and 95% CI:1.10 [1.00,1.22] and 1.04 [0.97,1.12],respectively).Adverse events appeared in 3 participants in the BXD group and 26 participants in the conventional therapy group.The quality of the trials included in this review was not very good.Conclusion:BXD has a superior effect to standard conventional therapy in improving clinical symptoms and repair of the mucosal lesion,and a similar effect to standard conventional therapy in clearing H.pylori.We still need good quality trials,especially placebo-controlled trials,in the future to confirm this result.

Explanation of Banxia Xiexin decoction based on “Xinkai Kujiang”

Banxia Xiexin decoction(BXD)is a representative formula of Zhang Zhongjing(Eastern Han Dynasty)for the treatment of pi syndrome,which is a combination of cold and heat,and its application in the treatment of digestive system diseases is remarkable.In this paper,we discuss how Chinese medicine recognizes“spleen”and“Pi syndrome”to explain and explore the basis of BXD prescription and analyze both clinical examples and drug toxicity to provide more basis for the clinical application of BXD.

UPLC-Q-TOF/MS-Based Serum Metabolomics Reveals Potential Anti-tumor Mechanism of Banxia Xiexin Decoction in Colorectal Cancer Mice

Objective To clarify the potential mechanism of Banxia Xiexin Decoction(BXD)on colorectal cancer(CRC)from the perspective of metabolomics.Methods Forty male C57BL/6 mice were randomly divided into normal control(NC),azoxymethane/dextran sulfate sodium(AOM/DSS)model,low-dose BXD(L-BXD),high-dose BXD(H-BXD)and mesalamine(MS)groups according to a random number table,8 mice in each group.Colorectal cancer model was induced by AOM/DSS.BXD was administered daily at doses of 3.915(L-BXD)and 15.66 g/kg(H-BXD)by gavage for consecutive 21 days,and 100 mg/kg MS was used as positive control.Following the entire modeling cycle,colon length of mice was measured and quantity of colorectal tumors were counted.The spleen and thymus index were determined by calculating the spleen/thymus weight to body weight.Inflammatory cytokine and changes of serum metabolites were analyzed by enzyme-linked immunosorbent assay kits and ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry(UPLC-Q/TOF-MS),respectively.Results Notably,BXD supplementation protected against weight loss,mitigated tumor formation,and diminished histologic damage in mice treated with AOM/DSS(P<0.05 or P<0.01).Moreover,BXD suppressed expression of serum inflammatory enzymes,and improved the spleen and thymus index(P<0.05).Compared with the normal group,102 kinds of differential metabolites were screened in the AOM/DSS group,including 48 potential biomarkers,involving 18 main metabolic pathways.Totally 18 potential biomarkers related to CRC were identified,and the anti-CRC mechanism of BXD was closely related to D-glutamine and D-glutamate metabolism,phenylalanine,tyrosine and tryptophan biosynthesis,arginine biosynthesis,nitrogen metabolism and so on.Conclusion BXD exerts partial protective effects on AOM/DSS-induced CRC by reducing inflammation,protecting organism immunity ability,and regulating amino acid metabolism.

Banxia Xiexin Decoction Alleviated Cerebral Glucose Metabolism Disorder by Regulating Intestinal Microbiota in APP/PS1 Mice

Objective To identify whether Banxia Xiexin Decoction(BXD)alleviates cerebral glucose metabolism disorder by intestinal microbiota regulation in APP/PS1 mice.Methods Forty-five 3-month-old male APP/PS1 mice were divided into 3 groups using a random number table(n=15 per group),including a model group(MG),a liraglutide group(LG)and a BXD group(BG).Fifteen 3-month-old male C57BL/6J wild-type mice were used as the control group(CG).Mice in the BG were administered BXD granules by gavage at a dose of 6 g/(kg·d)for 3 months,while mice in the LG were injected intraperitoneally once daily with Liraglutide Injection(25 nmol/kg)for 3 months.Firstly,liquid chromatography with tandem-mass spectrometry was used to analyze the active components of BXD granules and the medicated serum of BXD.Then,the cognitive deficits,Aβpathological change and synaptic plasticity markers,including synaptophysin(SYP)and postsynaptic density protein 95(PSD95),were measured in APP/PS1 mice.Brain glucose uptake was detected by micropositron emission tomography.Intestinal microbial constituents were detected by 16S rRNA sequencing.The levels of intestinal glucagon-like peptide 1(GLP-1)and cerebral GLP-1 receptor(GLP-1R),as well as the phosphoinositide-3-kinase/protein kinase B/glycogen synthase kinase-3β(PI3K/Akt/GSK3β)insulin signaling pathway were determined by immunohistochemical(IHC)staining and Western blot analysis,respectively.Results BXD ameliorated cognitive deficits and Aβpathological features(P<0.01).The expressions of SYP and PSD95 in the BG were higher than those in the MG(P<0.01).Brain glucose uptake in the BG was higher than that in the MG(P<0.01).The intestinal microbial composition in the BG was partially reversed.The levels of intestinal GLP-1 in the BG were higher than those in the MG(P<0.01).Compared with the MG,the expression levels of hippocampal GLP-1R,Akt,PI3K and p-PI3K in the BG were significantly increased(P<0.01),while the levels of GSK3βwere reduced(P<0.01).Conclusion BXD exhibited protective effects against Alzheimer’s disease by regulating the gut microbiota/GLP-1/GLP-1R,enhancing PI3K/Akt/GSK3βinsulin signaling pathway,and improving brain glucose metabolism.

半夏泄心汤全方及其拆方联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对炎性因子水平的影响

目的:探究半夏泄心汤全方及其拆方联合美沙拉嗪治疗溃疡性结肠炎的应用效果。方法:选取2023年5月~2024年5月在吉林省人民医院消化科和中医科诊治的120例中度溃疡性结肠炎患者作为研究对象。随机分为对照组(24例)与观察组(96例)。观察组分为全方组、辛开组、苦降组、甘补组,每组24例。对照组与观察组同时给药美沙拉嗪肠溶片。连续治疗3个月,比较对照组与观察组治疗前后的肠道内窥镜及外周血血清炎性因子水平。记录药物的不良反应。结果:观察组与对照组均表现出不同程度的治疗效果。对照组美沙拉嗪可以通过抑制炎性反应达到治疗结肠炎的作用。半夏泻心汤及拆方联合美沙拉嗪治疗结肠炎表现出良好的效果。辛开组具有温暖中焦脾胃的功效,能够偏向缓解患者呕吐,腹痛等症状。苦降组由于具有较多生物碱、黄酮类成分,具有较强的止泻、抗菌、消炎的功效。甘补组虽然能够大补元气提高患者免疫力,但由于患者肠道功能退化,并不能起到良好的效果。结论:半夏泻心汤全方联合美沙拉嗪可以有效缓解结肠炎症状并提高疗效。不同组方偏向不同,但单纯运用甘补类药材,不适宜肠胃功能较差的患者。

半夏泻心汤对功能性消化不良大鼠抑郁状态及促肾上腺皮质激素释放因子相关通路的影响

目的:观察半夏泻心汤对功能性消化不良(FD)大鼠抑郁样行为、下丘脑促肾上腺皮质激素释放因子(CRF)及其受体CRF-R1、CRF-R2的影响。方法:48只SPF级Wistar大鼠随机分为空白组、模型组、氟西汀组、半夏泻心汤低、中、高剂量组,共六组,每组各8只。空白组正常饲养,其余五组采用不规则喂养+夹尾激惹刺激法造模,造模成功后半夏泻心汤低、中、高各剂量组分别给予0.62、1.24、2.48 g/ml剂量灌胃,氟西汀组给予2 mg/kg氟西汀,空白组及模型组均给予同等容积的蒸馏水,各组连续灌胃14 d。干预结束后采用糖水偏好实验和旷场实验测试各组抑郁样行为;HE染色观察大鼠胃窦组织基本形态;RT-qPCR和Western blot检测大鼠下丘脑中CRF、CRF-R1和CRF-R2 mRNA和蛋白的表达。结果:与空白组比较,模型组大鼠体重、糖水偏好度、旷场实验移动总距离和直立次数均明显下降(P<0.05);下丘脑中CRF、CRF-R1 mRNA和蛋白表达均明显升高(P<0.01),CRF-R2 mRNA和蛋白的表达均明显降低(P<0.01)。与模型组比较,半夏泻心汤各剂量组大鼠的体重、糖水偏好度、旷场实验移动总距离和直立次数均明显增加(P<0.05);半夏泻心汤各剂量组FD大鼠下丘脑中CRF、CRF-R1 mRNA的表达量均明显降低(P<0.01),CRF-R2 mRNA的表达明显升高;半夏泻心汤高剂量组FD大鼠下丘脑中CRF蛋白表达均明显降低(P<0.01),半夏泻心汤各剂量组FD大鼠下丘脑中CRF-R1蛋白表达明显降低(P<0.01),CRF-R2蛋白表达升高(P<0.05)。结论:半夏泻心汤可通过调控CRF通路,恢复CRF-R1和CRF-R2的平衡状态,发挥抗抑郁的作用。

Effect of a modified Banxia Xiexin decoction plus chemotherapy on stage Ⅲ colon cancer

OBJECTIVE: To investigate the effect of a modified Banxia Xiexin decoction(MBXD) plus chemotherapy on postoperative adverse reaction in patients with stage Ⅲ colon cancer in patients whose symptoms were identified as cold-heat complicated pattern in terms of the theory of Traditional Chinese Medicine(TCM).METHODS: A prospective non-randomized control study of patients with stage Ⅲ colon cancer in Beijing Shijitan Hospital and Guang'anmen Hospital between January 2012 and December 2013. A total of 80 patients were divided into experimental group(MBXD + chemotherapy) and control group(chemotherapy). The adverse reactions, life quality and disease-free survival(DFS) were compared between the two groups.RESULTS: The cold-heat complex pattern was released in 94.3% of patients in experimental group whereas 62.2% in control group(P < 0.05). Life quality was improved in 24 vs 14 cases, stabilized in 9 vs14 cases whereas decreased in 2 vs 15 cases in experimental group and control group, respectively(P < 0.05). The average DFS was 22.371 months in experimental group, while 13.932 months in control group(P < 0.05).CONCLUSION: MBXD combined with chemotherapy may significantly relieve clinical symptoms, reduce chemotherapy associated adverse effects, improve life quality, and prolong DFS of patients with stage Ⅲ colon cancer(cold-heat complicated pattern).

祛湿通脉法治疗类风湿关节炎的研究与应用概况

基于类风湿关节炎患者“风湿瘀阻,筋伤骨损”的病机特点,提出“祛风除湿,通利血脉,畅通经络,健脾补肾,强筋壮骨”的治法,简称“祛湿通脉法”。在“祛湿通脉法”治疗原则的指导下,可根据正邪虚实,选用经验方如昆断益母方、南续益母颗粒、三藤舒筋方以及经方如桂枝芍药知母汤、黄芪桂枝五物汤、半夏泻心汤等进行随症加减的中药治疗,并可配合膏方、外治法、功能锻炼等,从而构建具有中医药优势的类风湿关节炎防治体系。该课题组所开展的系列临床和实验研究结果表明,“祛湿通脉法”治疗类风湿关节炎具有增效减毒的作用,是发挥中医药优势以防治类风湿关节炎的理论创新。

刘持年治疗胃痛常用经典名方中的药物辨析

分别从药物基源、用药部位、炮制规格、功效应用、用量用法及使用注意等方面,辨析刘持年治疗胃痛常用经典名方四逆散、半夏泻心汤、附子理中丸中的中药,主要包括柴胡、枳实、芍药、甘草、半夏、黄芩、黄连、干姜、人参、大枣、附子、白术等,明确处方的关键信息,为经典名方的合理应用提供参考。提出准确进行中药辨析,既是临床医生的基本功,也是中医药有效传承的重要内容。处方中药辨析,既要结合主治病证进行分析判断,也要尊古纳今,充分考虑当前的临床和生产实际,用历史和发展的角度去辨析,才能更加贴近和符合临床需求,真正促进中医发展和临床疗效的提高。

半夏泻心汤加味联合四联疗法对脾胃湿热型Hp相关慢性胃炎患者Hp清除率及胃肠黏膜功能的影响

[目的]探究半夏泻心汤加味联合四联疗法对脾胃湿热型幽门螺杆菌(Hp)相关慢性胃炎患者Hp清除率及胃肠黏膜功能的影响。[方法]收集2020年3月-2022年3月在本院收治的92例脾胃湿热型Hp相关慢性胃炎患者,将患者按照随机法分为对照组45例、研究组47例。对照组患者采用四联疗法予以治疗,而研究组患者则是在对照组的基础上联合半夏泻心汤加味进行治疗,比较两组患者的Hp清除率、胃肠黏膜功能、中医证候积分、胃肠道激素、临床疗效的情况变化。[结果]治疗后两组患者主症、次症积分、丙二醛(MDA)、血管活性肠肽(VIP)表达水平降低,胃泌素-17(GAS-17)、血清胃蛋白酶原I(PGI)、前列腺素E_(2)(PGE_(2))、胃动素、瘦素表达水平升高,且研究组较对照组有所改善(P<0.05)。与对照组比较,研究组的Hp清除率、临床总有效率升高(P<0.05)。研究组的临床总有效率比对照组高(P<0.05)。[结论]半夏泻心汤加味联合四联疗法对治疗脾胃湿热型Hp相关慢性胃炎患者效果显著,可有效减轻患者的中医症状,提升Hp清除率,调节体内的肠道菌群,改善胃肠黏膜功能,值得临床应用。

半夏泻心汤治疗消化系统疾病研究进展及质量标志物预测分析

半夏泻心汤为2018年国家中医药管理局公布的首批百首经方之一,出自《伤寒杂病论》,主治寒热错杂之痞满证,现代临床广泛用于消化系统疾病。该文整理了半夏泻心汤的化学成分及其治疗消化系统疾病的临床应用和药理作用,并通过中药质量标志物“五原则”相关研究方法,预测了半夏泻心汤治疗消化系统疾病的质量标志物,为其治疗消化系统疾病质量标准提供参考。

半夏泻心汤治疗功能性消化不良的机制研究

目的 评估不同功能性消化不良(FD)造模方法的效果,并探讨半夏泻心汤对FD的治疗作用及潜在机制。方法 BALB/c小鼠随机分为空白组、碘乙酰胺组、洛哌丁胺组、夹尾组和食醋组。经过1周干预,观察各组小鼠状态并检测其胃肠动力、激素水平及病理变化,评估并确定一种较为理想的FD造模方法。造模后给予不同剂量半夏泻心汤进行干预,观察小鼠胃肠功能的改变,并通过免疫组化、ELISA、Western blot等实验方法研究相关蛋白表达情况。结果 对4种造模方法进行比较发现,碘乙酰胺组、洛哌丁胺组和食醋组小鼠与空白组相比体质量有所减轻;碘乙酰胺组和食醋组小鼠胃排空率及小肠推进率下降;夹尾组及食醋组小鼠血清中胃肠激素发生变化。最后评估碘乙酰胺法为最优的FD造模方法。给药结果显示半夏泻心汤对FD小鼠进食量及体质量无明显影响,中、高剂量可改善FD小鼠身体状态,提高其胃排空率与小肠推进率。免疫组织化学、ELISA、Western blot等实验结果证实,中、高剂量半夏泻心汤可显著降低FD小鼠十二指肠及血清内TNF-α及IL-6的表达水平。结论 碘乙酰胺法是一种更优的FD造模方法。半夏泻心汤可改善FD小鼠状态,提高胃肠动力,通过降低炎症因子分泌达到治疗FD的作用。

半夏泻心汤治疗幽门螺杆菌阳性慢性萎缩性胃炎疗效及G-17、PGⅠ、PGⅡ水平分析

目的分析半夏泻心汤对幽门螺杆菌(helicobacter pylori,Hp)阳性慢性萎缩性胃炎(chronic atrophic gastritis,CAG)的疗效以及胃泌素17(gastrin 17,G-17)、胃蛋白酶Ⅰ(pepsinogenⅠ,PGⅠ)、胃蛋白酶原Ⅱ(pepsinogenⅡ,PGⅡ)水平的影响。方法选择2021年1月—2023年2月医院收治Hp阳性CAG患者总共98例进行研究,结合随机数字表法将其中49例归纳到对照组(常规西药治疗),余下49例归纳到观察组(于前组基础上加以半夏泻心汤),比较两组疗效、Hp根除比例、治疗前后中医证候积分、血清G-17、PGⅠ、PGⅡ水平和不良反应出现情况。结果观察组的有效率和Hp根除比例高于对照组(P<0.05)。治疗前,两组各项中医证候积分相比差异无统计学意义(P>0.05);治疗后,观察组各项中医证候积分低于对照组(P<0.05)。治疗前,两组血清G-17、PGⅠ、PGⅡ水平相比差异无统计学意义(P>0.05);治疗后,观察组血清G-17、PGⅠ、PGⅡ水平低于对照组(P<0.05)。两组不良反应相比差异无统计学意义(P>0.05)。结论半夏泻心汤对Hp阳性CAG患者疗效理想,能提高其Hp根除效果,改善其临床症状,促进G-17、PGⅠ、PGⅡ分泌,且安全性较高,值得采用。

半夏泻心汤化学成分、药理作用的研究进展及质量标志物的预测

半夏泻心汤(BXD)是记载于《伤寒论》中的经典名方之一,具有调和肝脾、寒热平调、消痞散结之功效。研究发现BXD具有保护胃肠道黏膜、抗胃肠道肿瘤、调节肠道菌群、降血糖、改善胰岛素抵抗、调节神经递质、抗抑郁等作用。通过对BXD的化学成分、药理作用研究进展进行归纳、总结与分析,并基于中药质量标志物(Q-marker)的传递与溯源、特有性、有效性、可测性及复方配伍环境对BXD的Q-marker进行预测分析,发现表小檗碱、黄连碱、巴马汀、小檗碱、黄芩苷、甘草酸、6-姜辣素、β-谷甾醇可作为BXD的Q-marker,以此为建立BXD及其复方制剂的质量控制体系和全过程质量溯源体系提供科学参考依据。